EGFR and non-small cell lung carcinoma: SHP2 pY62 has been reported as the single most differentially increased phosphosite in patients with EGFR-mutated non-small cell lung cancer (NSCLC), compared to their wild-type (WT) counterparts38 (Fig. 1E).